{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:40Z","timestamp":1792271380262,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Bordeaux, France and INSERM"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.phrs.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T11:54:59Z","timestamp":1523706899000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Human papillomavirus vaccine and demyelinating diseases\u2014A systematic review and meta-analysis"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6700-8520","authenticated-orcid":false,"given":"Julie","family":"Mouchet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-9595","authenticated-orcid":false,"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2018.04.007_bib0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1473-3099(03)00720-5","article-title":"Papillomavirus vaccines in clinical trials","volume":"3","author":"Galloway","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phrs.2018.04.007_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/DDDT.S91018","article-title":"Spotlight on the 9-valent HPV vaccine","volume":"11","author":"Lopalco","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2018.04.007_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00705-013-1827-z","article-title":"Human papillomavirus: current status and issues of vaccination","volume":"159","author":"Malik","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.phrs.2018.04.007_bib0020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"De Vincenzo","year":"2014","journal-title":"Int. J. Womens Health"},{"issue":"30","key":"10.1016\/j.phrs.2018.04.007_bib0025","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2010.04.070","article-title":"A summary of the post-licensure surveillance initiatives for GARDASIL\/SILGARD","volume":"28","author":"Bonanni","year":"2010","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.phrs.2018.04.007_bib0030","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2010.02.019","article-title":"Post-licensure monitoring of HPV vaccine in the United States","volume":"28","author":"Markowitz","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2018.04.007_bib0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clineuro.2016.03.023","article-title":"Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations","volume":"144","author":"Chang","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.007_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"21","key":"10.1016\/j.phrs.2018.04.007_bib0045","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2169\/internalmedicine.55.5472","article-title":"Two cases of acute disseminated encephalomyelitis following vaccination against human papilloma virus","volume":"55","author":"Sekiguchi","year":"2016","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.phrs.2018.04.007_bib0055","first-page":"472","article-title":"Demyelinating disease and vaccination of the human papillomavirus","volume":"52","author":"Alvarez-Soria","year":"2011","journal-title":"Rev. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.007_bib0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0883073809349322","article-title":"A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus","volume":"25","author":"DiMario","year":"2010","journal-title":"J. Child Neurol."},{"issue":"11","key":"10.1016\/j.phrs.2018.04.007_bib0065","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s00415-008-0867-x","article-title":"HPV vaccine: a cornerstone of female health a possible cause of ADEM?","volume":"255","author":"Schaffer","year":"2008","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.5665\/sleep.5752","article-title":"Risk of narcolepsy after AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine in adults: a case-coverage study in england","volume":"39","author":"Stowe","year":"2016","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.3220","article-title":"The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009\u20132010 seasonal influenza vaccines: results from self-controlled analyses","volume":"21","author":"Tokars","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"July (34)","key":"10.1016\/j.phrs.2018.04.007_bib0080","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1016\/j.vaccine.2014.06.022","article-title":"Recent progress and concerns regarding the Japanese immunization program: addressing the vaccine gap","volume":"32","author":"Saitoh","year":"2014","journal-title":"Vaccine"},{"issue":"9987","key":"10.1016\/j.phrs.2018.04.007_bib0085","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/S0140-6736(15)61152-7","article-title":"HPV vaccination crisis in Japan","volume":"385","author":"Hanley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.04.007_bib0090","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC)","author":"European Medicines Agency","year":"2018"},{"issue":"29","key":"10.1016\/j.phrs.2018.04.007_bib0095","first-page":"591","article-title":"Human papillomavirus vaccination coverage among adolescent girls, 2007\u20132012, and postlicensure vaccine safety monitoring, 2006\u20132013\u2013United States","volume":"62","author":"Prevention, C.f.D.C.a","year":"2013","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.phrs.2018.04.007_bib0100","article-title":"Vaccines and multiple sclerosis: a systematic review","author":"Mailand","year":"2016","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2018.04.007_bib0105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.autrev.2014.01.054","article-title":"On the relationship between human papilloma virus vaccine and autoimmune diseases","volume":"13","author":"Pellegrino","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2018.04.007_bib0110","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"15","key":"10.1016\/j.phrs.2018.04.007_bib0115","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2018.04.007_bib0125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.007_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2018.04.007_bib0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"11","key":"10.1016\/j.phrs.2018.04.007_bib0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.phrs.2018.04.007_bib0145","series-title":"Section 801 of the Food and Drug Administration Amendments Act (FDAAA 801)","author":"Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.phrs.2018.04.007_bib0150","volume":"Vol. 4","author":"Higgins","year":"2011"},{"key":"10.1016\/j.phrs.2018.04.007_bib0155","series-title":"Newcastle-Ottawa Scale","first-page":"2006","author":"Wells","year":"2006"},{"issue":"4","key":"10.1016\/j.phrs.2018.04.007_bib0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.phrs.2018.04.007_bib0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2018.04.007_bib0170","series-title":"ANSM\/CNAMTS\u2013Vaccin anti-HPV et risque de maladies auto-immunes: \u00e9tude pharmaco\u00e9pid\u00e9miologique. Rapport final","author":"Alp\u00e9rovitch","year":"2015"},{"key":"10.1016\/j.phrs.2018.04.007_bib0175","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papillomavirus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.phrs.2018.04.007_bib0185","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/ciw224","article-title":"Case-centered analysis of optic neuritis after vaccines","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2018.04.007_bib0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2018.04.007_bib0200","first-page":"1","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.phrs.2018.04.007_bib0205","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2018.04.007_bib0215","first-page":"1","article-title":"Evaluation of optic neuritis following human papillomavirus vaccination","author":"Sridhar","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"51","key":"10.1016\/j.phrs.2018.04.007_bib0220","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","article-title":"Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines","volume":"26","author":"Verstraeten","year":"2008","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"11","key":"10.1016\/j.phrs.2018.04.007_bib0230","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2018.04.007_bib0235","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imj.13005","article-title":"Adverse event monitoring of the human papillomavirus vaccines in Scotland","volume":"46","author":"Cameron","year":"2016","journal-title":"Intern. Med. J."},{"issue":"46","key":"10.1016\/j.phrs.2018.04.007_bib0240","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.phrs.2018.04.007_bib0245","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10067-014-2846-1","article-title":"A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events","volume":"34","author":"Geier","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0250","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12026-016-8815-9","article-title":"Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database","volume":"65","author":"Geier","year":"2017","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.007_bib0255","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1071\/SH09153","article-title":"Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance","volume":"7","author":"Gold","year":"2010","journal-title":"Sex. Health"},{"issue":"2","key":"10.1016\/j.phrs.2018.04.007_bib0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JRS-2011-0529","article-title":"Postlicensure safety evaluation of human papilloma virus vaccines","volume":"23","author":"Labadie","year":"2011","journal-title":"Int. J. Risk Saf. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0265","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.26292","article-title":"Guillain\u2013Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States","volume":"10","author":"Ojha","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"10","key":"10.1016\/j.phrs.2018.04.007_bib0270","doi-asserted-by":"crossref","first-page":"e77766","DOI":"10.1371\/journal.pone.0077766","article-title":"Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems","volume":"8","author":"Pellegrino","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2018.04.007_bib0275","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0280","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain\u2013Barr\u00e9 syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006\u20132009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.phrs.2018.04.007_bib0285","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006\u20132015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"11","key":"10.1016\/j.phrs.2018.04.007_bib0290","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum. Vaccine Immunother."},{"key":"10.1016\/j.phrs.2018.04.007_bib0295","unstructured":"K. Stratton, D. Almario, M.C. McCormick, Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders 2002 Washington (DC)."},{"issue":"4","key":"10.1016\/j.phrs.2018.04.007_bib0300","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi\u2010Bensouda","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2018.04.007_bib0305","first-page":"150","article-title":"Postmarketing spontaneous pharmacovigilance reporting systems","volume":"5","author":"Dal Pan","year":"2012","journal-title":"Pharmacoepidemiology"},{"key":"10.1016\/j.phrs.2018.04.007_bib0310","series-title":"Seminars in Neurology","article-title":"Guillain-Barr\u00e9 syndrome","author":"Burns","year":"2008"},{"issue":"9","key":"10.1016\/j.phrs.2018.04.007_bib0315","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta\u2010analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.phrs.2018.04.007_bib0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.007_bib0325","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/sim.4780090307","article-title":"Bias in the one-step method for pooling study results","volume":"9","author":"Greenland","year":"1990","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0330","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.007_bib0335","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Methods"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T15:34:29Z","timestamp":1604158469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818302883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":67,"alternative-id":["S1043661818302883"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.007","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccine and demyelinating diseases\u2014A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}